Anti-TNF-Alpha Therapy and Systemic Vasculitis

Table 4

Open label and randomized controlled trials performed in Behcet’s uveitis.

References	Design/anti-TNF-α therapy	Number of patients	Main objectives	Follow-up	Main results	Side effects
Okada et al. [56]	Open label trial IFX	63	Efficacy of IFX in the first year of treatment	12 months	Improvement in 69% Improvement somewhat in 23%; Unchanged in 8%	46% of side effects including 3 infusion reactions; No serious side effects
Sfikakis et al. [57]	Open label trial IFX	25	Remission at day 28	28 days	89% of complete remission	No serious side effects
Ohno et al. [58]	Open label trial IFX	12	Frequency of ocular attacks	14 weeks	Reduction in the number of relapses for IFX (5 mg/kg and 10 mg/kg)	One case of tuberculosis (IFX 10 mg/kg)
Accorinti et al. [59]	Open label trial IFX	12	Frequency of ocular attacks	15 months	91% of reduction in the number of relapses	33% of side effects including one tuberculosis and one herpetic keratitis
Tognon et al. [60]	Open label trial IFX	7	Frequency of ocular attacks	23 months	21 to 6 ocular attacks observed in the equivalent period of time before treatment	One infusion reaction
Tugal-Tutkun et al. [61]	Open label trial IFX	13	Absence of ocular attacks	6 years	31% remained attack-free 32 to 13 ocular attacks observed in the equivalent period of time before treatment	No serious side effects (7 respiratory tract infection and one infusion reaction)